Baxter International Inc. (BAX)
| Market Cap | 9.70B -37.7% |
| Revenue (ttm) | 11.32B +5.1% |
| Net Income | -1.10B |
| EPS | -2.14 |
| Shares Out | 516.47M |
| PE Ratio | n/a |
| Forward PE | 9.58 |
| Dividend | $0.04 (0.21%) |
| Ex-Dividend Date | May 29, 2026 |
| Volume | 8,489,136 |
| Open | 19.06 |
| Previous Close | 19.24 |
| Day's Range | 18.77 - 19.18 |
| 52-Week Range | 15.73 - 32.04 |
| Beta | 0.62 |
| Analysts | Hold |
| Price Target | 21.54 (+16.93%) |
| Earnings Date | Apr 30, 2026 |
About BAX
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies;... [Read more]
Financial Performance
In 2025, Baxter International's revenue was $11.24 billion, an increase of 5.72% compared to the previous year's $10.64 billion. Losses were -$957.00 million, 47.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for BAX stock is "Hold." The 12-month stock price target is $21.54, which is an increase of 16.93% from the latest price.
News
Baxter downgraded to Sell from Neutral at Citi
Citi analyst Joanne Wuensch downgraded Baxter (BAX) to Sell from Neutral with a price target of $17, down from $19. The company faces a back-half weighted year and is searching…
Baxter International Transcript: Bank of America Global Healthcare Conference 2026
Management detailed ongoing cultural and operational transformation, emphasizing accountability, decentralized decision-making, and improved incentive alignment. Portfolio stabilization, margin expansion, and free cash flow improvement are key priorities, with capital allocation flexibility expected once leverage falls below 3x.
Baxter International Shareholders Approve Board Slate, Pay and Incentive Plan at Annual Meeting
Baxter International NYSE: BAX held its 2026 annual meeting of stockholders by webcast, with shareholders giving preliminary approval to all five proposals presented by the company, including the elec...
Baxter International Transcript: AGM 2026
The meeting covered board updates, five key proposals, and voting outcomes. All proposals, including director elections, executive compensation, auditor ratification, incentive plan, and board size amendment, were approved by strong majorities. Final results will be filed on Form 8-K.
Baxter price target raised to $27 from $25 at Barclays
Barclays raised the firm’s price target on Baxter (BAX) to $27 from $25 and keeps an Overweight rating on the shares. The comapny surprised investors expecting a guidance cut with…
Baxter price target lowered to $17 from $19 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Baxter (BAX) to $17 from $19 and keeps a Neutral rating on the shares. Baxter’s Q1 results reflected ongoing operational and margin…
Baxter International Earnings Call Transcript: Q1 2026
First quarter results were in line with expectations, with reported sales up 3% but organic sales down 1% and adjusted EPS down 35% year-over-year. Guidance for 2026 is reiterated, with flat organic sales and improved performance expected in the second half, supported by new product launches and operational improvements.
Baxter International Slides: Q1 2026
Baxter International has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Baxter International Earnings release: Q1 2026
Baxter International released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Baxter International Quarterly report: Q1 2026
Baxter International has published its Q1 2026 quarterly earnings report on April 30, 2026.
Baxter beats quarterly expectations on strong demand for medical devices
Baxter on Thursday beat Wall Street estimates for first-quarter profit and revenue, helped by robust sales in its medical products and therapies unit.
Baxter Reports First-Quarter 2026 Results
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX), a global medtech leader, today reported results for the first quarter of 2026. “Financial results for the quarter overall were ...
Baxter International Proxy statement: Proxy filing
Baxter International filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Baxter showcases Global Surgical Solutions portfolio at AORN Conference
Baxter (BAX) International is highlighting recent additions to its Global Surgical Solutions and Patient Support Systems portfolios, as well as its broad Advanced Surgery portfolio of hemostatic and s...
Baxter Showcases Recent Innovations at AORN Global Surgical Conference & Expo 2026
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, is highlighting recent additions to its Global Surgical Solutions and Patient Support Systems portfolio...
Baxter to Host First-Quarter 2026 Financial Results Conference Call for Investors
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its first-quarter 2026 financial results on Thursday, A...
Baxter price target lowered to $22 from $23 at Evercore ISI
Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Baxter (BAX) to $22 from $23 and keeps an Outperform rating on the shares as part of the firm’s…
Baxter introduces IV Verify Line Labeling System
Baxter (BAX) International debuted the IV Verify Line Labeling System, an automated solution, at the 2026 American Organization for Nursing Leadership Conference. The IV Verify system is designed to s...
Baxter Introduces the IV Verify Line Labeling System, an Automated Solution to Improve IV Labeling in Healthcare Settings
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and platforms, today debuted the IV Verify Line Labeling System, an automated solutio...
Baxter to Host Annual Meeting of Stockholders in Virtual Format
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2026 Annual Meeting) in a virtual format on Tuesday, ...
Pet Partners and the Baxter Foundation Expand Therapy Animal Programs to Support 100,000 Patients and Healthcare Workers in Two-Year Pilot
Largest Single Investment from a Corporate Foundation Aims to Strengthen Healthcare Resilience by Advancing Therapy Animal Visits in U.S. Healthcare Settings BELLEVUE, Wash. and DEERFIELD, Ill.
EU regulator warns of shortage in Baxter's cancer treatment until early 2027
The European Union's medicines regulator said on Tuesday it expects Baxter International's cancer drugs containing ifosfamide will remain in shortage in the bloc well into the first quarter of next ...
Baxter International Proxy statement: Proxy filing
Baxter International filed a proxy statement on March 23, 2026, providing details for shareholder voting and corporate governance matters.
Baxter International Proxy statement: Proxy filing
Baxter International filed a proxy statement on March 23, 2026, providing details for shareholder voting and corporate governance matters.